Prism MarketView

November 19, 2024 at 12:20 pm

Former Biotech CEO and Trump Appointee Vivek Ramaswamy Slams FDA Bureaucracy for Stifling Innovation and Driving Up Drug Costs

If former biotech entrepreneur Vivek Ramaswamy has his way, things will look a lot different at the FDA in the next four years. Ramaswamy and… [Read More]

October 21, 2024 at 12:55 pm

Trevi Therapeutics Completes Enrollment for Phase 2a Chronic Cough Trial; Topline Results Expected Q1 2025

Trevi Therapeutics (Nasdaq: TRVI) has completed enrollment for its Phase 2a trial evaluating Haduvio™ (oral nalbuphine ER) for the treatment of refractory chronic cough (RCC)…. [Read More]

October 21, 2024 at 12:01 pm

PharmAla’s LaNeo MDMA to Power Mt. Sinai Clinical Trial; Shares Surge 27%

PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTC: MDXXF) has announced it will supply its GMP-grade LaNeo™ MDMA to a clinical trial at Mt. Sinai Health… [Read More]

October 21, 2024 at 9:58 am

IceCure Wins U.S. Patent for Next-Generation Cryoablation System; Stock Trading Up 10%

IceCure Medical Ltd. (Nasdaq: ICCM) has secured a Notice of Allowance from the U.S. Patent and Trademark Office for its innovative “Cryogenic System Connector.” This… [Read More]

October 21, 2024 at 8:54 am

Breakthrough Preclinical Results: MIRA Pharmaceuticals’ Ketamir-2 Surpasses Leading Neuropathic Pain Treatments

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) reports that its novel oral ketamine analog, Ketamir-2, has outperformed FDA-approved neuropathic pain treatments Gabapentin and Pregabalin in a recent… [Read More]

October 18, 2024 at 11:04 am

Immutep Advances First-in-Human Phase I Study of IMP761 to Dose Escalation Phase

Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company focused on LAG-3 immunotherapies, announced that its first-in-human Phase I study of IMP761 has progressed… [Read More]

August 30, 2024 at 3:07 pm

PRISM Weight Loss Index Leader LEXX Soars 24% on Positive DehydraTECH-Processed Rybelsus® Study Results

Lexaria Bioscience Corp. (NASDAQ: LEXX), today’s standout in the PRISM Weight Loss Index, saw its shares surge 24% following the announcement of promising results from… [Read More]

July 11, 2024 at 9:19 am

Oncocyte CEO Josh Riggs on Market Disruption, Product Market Fit and Future Outlook Featured on MedTech Guru’s Podcast

CEO Josh Riggs of the molecular diagnostics technology company, Oncocyte (OCX) was featured on the MedTech Guru’s latest podcast episode 247, “Take Advantage of the… [Read More]

July 08, 2024 at 10:56 am

Annovis Bio Shares Soar on New Phase 3 Data in Parkinson’s Disease

Shares in late-stage clinical drug platform company Annovis Bio (Nasdaq: ANVS) soared nearly 40% on Friday after the company announced new data from its Phase… [Read More]

June 26, 2024 at 4:04 pm

Is Biotech Back? IPO and M&A Activity Points to Resurgence

Biotechnology struggled in the public equity markets in 2023, hit by a combination of depressed investor sentiment, regulatory challenges, geopolitical tensions, and supply chain disruptions. … [Read More]

June 24, 2024 at 12:58 pm

Altimmune Obesity Drug Provides Class-Leading Lean Mass Preservation

Clinical-stage biopharmaceutical company, Altimmune, Inc (Nasdaq: ALT) topped the PRISM Global Health Index on Monday morning after the company presented data from a 48-week Phase… [Read More]

May 20, 2024 at 4:44 pm

NKGen to Progress Alzheimer’s Candidate into Phase 2; Shares Surge 75%

Shares in biotechnology company, NKGen Biotech (Nasdaq: NKGN) soared more than 75% in morning trading on Monday after the company announced that its lead candidate… [Read More]

Tag: BIO TECH